Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

Market Cap	11.57B
Revenue (ttm)	5.71B
Net Income (ttm)	23.68M
Shares Out	3.00B
EPS (ttm)	0.01
PE Ratio	488.51
Forward PE	20.26
Dividend	0.03 (0.76%)
Ex-Dividend Date	May 23, 2024

Volume	76,868,405
Average Volume	103,037,542
Open	3.760
Previous Close	3.930
Day's Range	3.760 - 3.950
52-Week Range	3.010 - 4.870
Beta	-0.00
RSI	57.94
Earnings Date	Aug 29, 2025

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company offers Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, medical and healthcare services, and smart supply chain for pharmaceutical and medical devices. It also provides its products in the areas of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases, as wel...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 5,297
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2024, SHE:300026's revenue was 5.78 billion, a decrease of -5.34% compared to the previous year's 6.11 billion. Earnings were 21.47 million, a decrease of -95.76%.